REGiNA

The aim of the projects combined in the REGiNA indication area "musculoskeletal system" is to develop new, approvable cell therapies or to further develop existing forms of therapy in such a way that they can be made accessible to a larger group of patients. In the future, these new therapies will be used to treat injuries and chronic diseases of intervertebral discs, joint cartilage and bone healing disorders (pseudarthrosis). The strategy applied for all three therapeutic approaches is based on the combination of selected stem cell populations, a suitable biomaterial and optimized, GMP-compatible manufacturing processes. In addition to production and optimized cultivation, the main focus is on the characterization of cells and cell-populated biomaterials. The best possible description of the purity, identity and quality of the cell populations used as well as the quality and efficacy of the end product are basic prerequisites for later approval according to the new tissue law and the guidelines of the EMA (European Medicine Agency).